S8 Ep23: FDA Approval Insights: Pirtobrutinib in MCL

from OncLive® On Air · host OncLive® On Air

Dr Leslie discusses the FDA approval of pirtobrutinib in patients with MCL previously treated with a BTK inhibitor, key efficacy and safety findings from the BRUIN trial, and potential treatment sequencing strategies in patients with resistance to covalent BTK inhibitors.

Episode metadata supplied by the publisher feed · Published Feb 27, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

S8 Ep23: FDA Approval Insights: Pirtobrutinib in MCL

0:00 6:29

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 6 minutes long.

When was this OncLive® On Air episode published?

This episode was published on February 27, 2023.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!